21-Aug-2026
Canaccord Genuity Reaffirms Their Hold Rating on InMode (INMD)
TipRanks (Mon, 17-Aug 8:20 AM ET)
PRNewswire (Wed, 5-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 9:05 AM ET)
Business Wire (Tue, 28-Jul 4:00 PM ET)
Business Wire (Thu, 16-Jul 4:10 PM ET)
PRNewswire (Mon, 13-Jul 7:00 AM ET)
InMode Confirms Receipt of Unsolicited Proposal
PRNewswire (Fri, 10-Jul 7:00 AM ET)
Steel Partners Offers to Acquire InMode for $16.75 Per Share in Cash
Business Wire (Thu, 9-Jul 8:35 AM ET)
Business Wire (Thu, 2-Jul 1:19 PM ET)
Business Wire (Thu, 2-Jul 9:00 AM ET)
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Inmode Ltd. - trades on the NASDAQ stock market under the symbol INMD.
As of August 21, 2026, INMD stock price climbed to $15.06 with 270,548 million shares trading.
INMD has a beta of 0.43, meaning it tends to be less sensitive to market movements. INMD has a correlation of 0.04 to the broad based SPY ETF.
INMD has a market cap of $865.66 million. This is considered a Small Cap stock.
Last quarter Inmode Ltd. - reported $96 million in Revenue and $.35 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.02.
In the last 3 years, INMD traded as high as $40.40 and as low as $12.72.
The top ETF exchange traded funds that INMD belongs to (by Net Assets): IEFA, SCZ, IXUS, IZRL, EIS.
INMD has underperformed the market in the last year with a price return of +6.0% while the SPY ETF gained +21.7%. However, in the short term, INMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +8.9% vs +3.4% return in SPY. But in the last 2 weeks, INMD shares have been beat by the market, returning -1.6% compared to an SPY return of -1.0%.
INMD support price is $14.74 and resistance is $15.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMD shares will trade within this expected range on the day.
